NCT04398043

Brief Summary

SARS-CoV-2 transmission is frequently occurring in hospital settings, with numerous reported cases of nosocomial transmission highlighting the vulnerability of healthcare workers. If products proved to be efficacious against COVID-19, why are so many HCW getting COVID-19? Is it related to experience? Is it generated by the exhaustive job? Is there any degree of relationship to stress? These questions are still without fully correct answers. Achieving global benefits for HCW is still waiting.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2020

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 15, 2020

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

May 19, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 21, 2020

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2020

Completed
Last Updated

May 21, 2020

Status Verified

May 1, 2020

Enrollment Period

2 months

First QC Date

May 19, 2020

Last Update Submit

May 20, 2020

Conditions

rt PCRCOVIDPersonal Protective Equipment PPESARS-CoV 2Health Personnel AttitudeVirus Diseases

Outcome Measures

Primary Outcomes (1)

  • Asses surface contamination personel protective equipment

    To assess the prevalence of surface contamination with COVID-19 from personal protective equipment (PPE) worn by medical doctors, immediately after evaluating sick patients

    2 months

Secondary Outcomes (2)

  • Virus charge cuantification

    2 months

  • Place in PPE contamination

    2 month

Other Outcomes (1)

  • Prevention risk advice

    2 month

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

In patients in a University Hospital with COVID 19 desease

You may qualify if:

  • in patient with rtPCT possitive for SARSCoV-2 (interned in an intensive care unit, medical clinic room and coronary unit)

You may not qualify if:

  • in pattient with negattive rtPCT for SARSCoV-2

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (6)

  • The Lancet. COVID-19: protecting health-care workers. Lancet. 2020 Mar 21;395(10228):922. doi: 10.1016/S0140-6736(20)30644-9. No abstract available.

    PMID: 32199474BACKGROUND

  • Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality. Environ Int. 2020 Jun;139:105730. doi: 10.1016/j.envint.2020.105730. Epub 2020 Apr 10.

    PMID: 32294574BACKGROUND

  • Meselson M. Droplets and Aerosols in the Transmission of SARS-CoV-2. N Engl J Med. 2020 May 21;382(21):2063. doi: 10.1056/NEJMc2009324. Epub 2020 Apr 15. No abstract available.

    PMID: 32294374BACKGROUND

  • Assessment of N95 respirator decontamination and re-use for SARS-CoV-2 Robert Fischer, View ORCID ProfileDylan H Morris, Neeltje van Doremalen, Shanda Sarchette, Jeremiah Matson, Trenton Bushmaker, Claude Kwe Yinda, Stephanie Seifert, Amandine Gamble, Brandi Williamson, Seth Judson, Emmie de Wit, Jamie Lloyd-Smith, View ORCID ProfileVincent Munster doi: https://doi.org/10.1101/2020.04.11.20062018

    BACKGROUND

  • Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. Emerg Microbes Infect. 2020 Dec;9(1):747-756. doi: 10.1080/22221751.2020.1745095.

    PMID: 32196430BACKGROUND

  • Maguire BJ, Guerin PJ. A living systematic review protocol for COVID-19 clinical trial registrations. Wellcome Open Res. 2020 Apr 2;5:60. doi: 10.12688/wellcomeopenres.15821.1. eCollection 2020.

    PMID: 32292826BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

The viral RNA of the sample will be purified using a commercial kit according to the manufacturer's instructions. Detection of SARS-CoV-2 will be performed on the viral RNA obtained from these samples by real-time RT-PCR according to the protocol of the US Center for Disease Control.

MeSH Terms

Conditions

Virus Diseases

Condition Hierarchy (Ancestors)

Infections

Study Officials

  • Claudio Yaryour, MD

    Hospital de Clínicas José de San Martín, UBA

    STUDY CHAIR

Central Study Contacts

bernardo bergroth, MD

CONTACT

+5491137047513bernibergroth@gmail.com

Claudio Yaryour, MD

CONTACT

chyaryour@hotmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Chief of medical informatics

Study Record Dates

First Submitted

May 19, 2020

First Posted

May 21, 2020

Study Start

May 15, 2020

Primary Completion

June 30, 2020

Study Completion

July 30, 2020

Last Updated

May 21, 2020

Record last verified: 2020-05